{"protocolSection":{"identificationModule":{"nctId":"NCT00065182","orgStudyIdInfo":{"id":"104864/615"},"secondaryIdInfos":[{"id":"2004-002892-17","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer","officialTitle":"WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL"},"statusModule":{"statusVerifiedDate":"2019-03","overallStatus":"COMPLETED","startDateStruct":{"date":"2003-08-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2007-08-30","type":"ACTUAL"},"completionDateStruct":{"date":"2007-08-30","type":"ACTUAL"},"studyFirstSubmitDate":"2003-07-17","studyFirstSubmitQcDate":"2003-07-17","studyFirstPostDateStruct":{"date":"2003-07-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-09-07","resultsFirstSubmitQcDate":"2019-03-29","resultsFirstPostDateStruct":{"date":"2019-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-03-29","lastUpdatePostDateStruct":{"date":"2019-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN."},"conditionsModule":{"conditions":["Lung Cancer, Non-Small Cell","Non-Small-Cell Lung Cancer"],"keywords":["HYCAMTIN","TAXOTERE","non-small cell lung cancer","NSCLC","docetaxel","topotecan","Stage IIIB/IV","Advanced"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":399,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Topotecan/Docetaxel combination"},{"type":"DRUG","name":"Docetaxel","otherNames":["Topotecan/Docetaxel combination"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Median Time of Overall Survival","description":"Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.","timeFrame":"Up to one year from Day -1 (randomization)"}],"secondaryOutcomes":[{"measure":"Number of Participants With One-year Survival","description":"Number of participants with one-year survival were planned to be reported.","timeFrame":"Up to one year from Day -1 (randomization)"},{"measure":"Median Time to Progression","description":"Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.","timeFrame":"Up to one year from Day -1 (randomization)"},{"measure":"Response Rate","description":"Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.","timeFrame":"Up to one year from Day -1 (randomization)"},{"measure":"Response Duration","description":"Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.","timeFrame":"Up to one year from Day -1 (randomization)"},{"measure":"Time to Response-assessed Every 8 Weeks","description":"Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.","timeFrame":"Every 8 Weeks post randomization"},{"measure":"Assessment of Quality of Life-assessed Every 4 Weeks","description":"The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).","timeFrame":"Every 4 Weeks post randomization"},{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.","timeFrame":"Up to 16 months"},{"measure":"Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities","description":"Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.","timeFrame":"Up to 16 months"},{"measure":"Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities","description":"Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.","timeFrame":"Up to 16 months"},{"measure":"Number of Participants With Clinically Significant Abnormal Vital Signs Data","description":"Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.","timeFrame":"Up to 16 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Written informed consent\n* At least 18 years old\n* Confirmed advanced non-small cell lung carcinoma (NSCLC)\n* Received one prior chemotherapy for metastatic NSCLC excluding TAXOTERE or HYCAMTIN. In addition, subjects are allowed to have previously received a non-cytotoxic therapy, such as an endothelial growth factor receptor (EGFR) or angiogenesis inhibitor.\n* Presence of either measurable or non-measurable disease by radiologic study or physical examination.\n* Full recovery and at least 21 days from prior treatment for NSCLC; 42 days from treatment with mitomycin or nitrosureas and 30 days from prior non-cytotoxic therapy.\n* At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient).\n* At least 7 days since prior radiotherapy.\n* A probable life expectance of at least 3 months.\n* Adequate bone marrow reserve, CBC/Platelet, kidney and liver function.\n\nExclusion criteria:\n\n* Concomitant malignancies or other malignancies within the last five years.\n* Symptoms of brain metastases requiring treatment with steroids.\n* Active infection.\n* Severe medical problems other than the diagnosis of NSCLC that would limit the ability of the subject to follow study guidelines or expose the subject to extreme risk.\n* Ongoing or planned chemotherapy (other than treatment during this study), immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC.\n* Use of investigational drug within 30 days or 5 half-lives prior to the first dose of study medication.\n* Women who are pregnant or lactating.\n* Subjects of child-bearing potential refusing to practice adequate contraception.\n* Prior treatment with or history of allergic reaction to either HYCAMTIN or TAXOTERE.\n* Subjects who cannot receive steroid premedication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"GSK Investigational Site","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"GSK Investigational Site","city":"Tucson","state":"Arizona","zip":"85712","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"GSK Investigational Site","city":"Little Rock","state":"Arkansas","zip":"72205","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"GSK Investigational Site","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"GSK Investigational Site","city":"Los Angeles","state":"California","zip":"90067","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"GSK Investigational Site","city":"Poway","state":"California","zip":"92064","country":"United States","geoPoint":{"lat":32.96282,"lon":-117.03586}},{"facility":"GSK Investigational Site","city":"Denver","state":"Colorado","zip":"80210","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"GSK Investigational Site","city":"Washington D.C.","state":"District of Columbia","zip":"20307-5001","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"GSK Investigational Site","city":"Washington D.C.","state":"District of Columbia","zip":"20422","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"GSK Investigational Site","city":"Boca Raton","state":"Florida","zip":"33428","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"GSK Investigational Site","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"GSK Investigational Site","city":"Lakeland","state":"Florida","zip":"33805","country":"United States","geoPoint":{"lat":28.03947,"lon":-81.9498}},{"facility":"GSK Investigational Site","city":"Miami Shores","state":"Florida","zip":"33138","country":"United States","geoPoint":{"lat":25.86315,"lon":-80.19283}},{"facility":"GSK Investigational Site","city":"Orange Park","state":"Florida","zip":"32073","country":"United States","geoPoint":{"lat":30.16607,"lon":-81.70648}},{"facility":"GSK Investigational Site","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"GSK Investigational Site","city":"Stuart","state":"Florida","zip":"34994","country":"United States","geoPoint":{"lat":27.19755,"lon":-80.25283}},{"facility":"GSK Investigational Site","city":"Columbus","state":"Georgia","zip":"31902","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"GSK Investigational Site","city":"Decatur","state":"Illinois","zip":"62526","country":"United States","geoPoint":{"lat":39.84031,"lon":-88.9548}},{"facility":"GSK Investigational Site","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"GSK Investigational Site","city":"Skokie","state":"Illinois","zip":"60077","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"GSK Investigational Site","city":"Urbana","state":"Illinois","zip":"61801","country":"United States","geoPoint":{"lat":40.11059,"lon":-88.20727}},{"facility":"GSK Investigational Site","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"GSK Investigational Site","city":"Bowling Green","state":"Kentucky","zip":"42101","country":"United States","geoPoint":{"lat":36.99032,"lon":-86.4436}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40215","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"GSK Investigational Site","city":"Lafayette","state":"Louisiana","zip":"70506","country":"United States","geoPoint":{"lat":30.22409,"lon":-92.01984}},{"facility":"GSK Investigational Site","city":"Lake Charles","state":"Louisiana","zip":"70601","country":"United States","geoPoint":{"lat":30.21309,"lon":-93.2044}},{"facility":"GSK Investigational Site","city":"Frederick","state":"Maryland","zip":"21701","country":"United States","geoPoint":{"lat":39.41427,"lon":-77.41054}},{"facility":"GSK Investigational Site","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"GSK Investigational Site","city":"Grosse Pointe Woods","state":"Michigan","zip":"48236","country":"United States","geoPoint":{"lat":42.44365,"lon":-82.90686}},{"facility":"GSK Investigational Site","city":"Minneapolis","state":"Minnesota","zip":"55407-3799","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"GSK Investigational Site","city":"Minneapolis","state":"Minnesota","zip":"55417","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"GSK Investigational Site","city":"Robbinsdale","state":"Minnesota","zip":"55422","country":"United States","geoPoint":{"lat":45.03219,"lon":-93.33856}},{"facility":"GSK Investigational Site","city":"Springfield","state":"Missouri","zip":"65807","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"GSK Investigational Site","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"GSK Investigational Site","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"GSK Investigational Site","city":"Buffalo","state":"New York","zip":"14215-1199","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"GSK Investigational Site","city":"East Syracuse","state":"New York","zip":"13057","country":"United States","geoPoint":{"lat":43.06534,"lon":-76.07853}},{"facility":"GSK Investigational Site","city":"Manhasset","state":"New York","zip":"11030","country":"United States","geoPoint":{"lat":40.79788,"lon":-73.69957}},{"facility":"GSK Investigational Site","city":"New Hyde Park","state":"New York","zip":"11040","country":"United States","geoPoint":{"lat":40.7351,"lon":-73.68791}},{"facility":"GSK Investigational Site","city":"Nyack","state":"New York","zip":"10960","country":"United States","geoPoint":{"lat":41.09065,"lon":-73.91791}},{"facility":"GSK Investigational Site","city":"Rochester","state":"New York","zip":"14623","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"GSK Investigational Site","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"GSK Investigational Site","city":"Fayetteville","state":"North Carolina","zip":"28302-2000","country":"United States","geoPoint":{"lat":35.05266,"lon":-78.87836}},{"facility":"GSK Investigational Site","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"GSK Investigational Site","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"GSK Investigational Site","city":"Dunmore","state":"Pennsylvania","zip":"18512","country":"United States","geoPoint":{"lat":41.4198,"lon":-75.63241}},{"facility":"GSK Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19114","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"GSK Investigational Site","city":"Columbia","state":"South Carolina","zip":"29203","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"GSK Investigational Site","city":"Hilton Head Island","state":"South Carolina","zip":"29926","country":"United States","geoPoint":{"lat":32.19382,"lon":-80.73816}},{"facility":"GSK Investigational Site","city":"Spartanburg","state":"South Carolina","zip":"29303","country":"United States","geoPoint":{"lat":34.94957,"lon":-81.93205}},{"facility":"GSK Investigational Site","city":"Knoxville","state":"Tennessee","zip":"37916","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"GSK Investigational Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"GSK Investigational Site","city":"Irving","state":"Texas","zip":"75038","country":"United States","geoPoint":{"lat":32.81402,"lon":-96.94889}},{"facility":"GSK Investigational Site","city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"GSK Investigational Site","city":"Abingdon","state":"Virginia","zip":"24211","country":"United States","geoPoint":{"lat":36.70983,"lon":-81.97735}},{"facility":"GSK Investigational Site","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"GSK Investigational Site","city":"Norfolk","state":"Virginia","zip":"23507","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"GSK Investigational Site","city":"Spokane","state":"Washington","zip":"99204","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"GSK Investigational Site","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"GSK Investigational Site","city":"Milwaukee","state":"Wisconsin","zip":"53295","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"GSK Investigational Site","city":"Sheboygan","state":"Wisconsin","zip":"53081","country":"United States","geoPoint":{"lat":43.75083,"lon":-87.71453}},{"facility":"GSK Investigational Site","city":"Casper","state":"Wyoming","zip":"85601","country":"United States","geoPoint":{"lat":42.86663,"lon":-106.31308}},{"facility":"GSK Investigational Site","city":"Calgary","state":"Alberta","zip":"T2N 4N2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"GSK Investigational Site","city":"Moncton","state":"New Brunswick","zip":"E1C 8X3","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"GSK Investigational Site","city":"Kingston","state":"Ontario","zip":"K7L 5P9","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48098}},{"facility":"GSK Investigational Site","city":"Kitchener","state":"Ontario","zip":"N2G 1G3","country":"Canada","geoPoint":{"lat":43.42537,"lon":-80.5112}},{"facility":"GSK Investigational Site","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"GSK Investigational Site","city":"Ottawa","state":"Ontario","zip":"K1H 1C4","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"GSK Investigational Site","city":"St. Catharines","state":"Ontario","zip":"L2R 5K3","country":"Canada","geoPoint":{"lat":43.17126,"lon":-79.24267}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M5G 1X5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"GSK Investigational Site","city":"Weston","state":"Ontario","zip":"M9N 1N8","country":"Canada","geoPoint":{"lat":43.70359,"lon":-79.51513}},{"facility":"GSK Investigational Site","city":"Greenfield Park","state":"Quebec","zip":"J4V 2H1","country":"Canada","geoPoint":{"lat":45.48649,"lon":-73.46223}},{"facility":"GSK Investigational Site","city":"Lévis","state":"Quebec","zip":"G6V 3Z1","country":"Canada","geoPoint":{"lat":46.80326,"lon":-71.17793}},{"facility":"GSK Investigational Site","city":"Sainte-Foy","state":"Quebec","zip":"G1V 4G5","country":"Canada","geoPoint":{"lat":46.78139,"lon":-71.29217}},{"facility":"GSK Investigational Site","city":"Kielce","zip":"25-640","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"GSK Investigational Site","city":"Krakow","zip":"31-115","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"GSK Investigational Site","city":"Olsztyn","zip":"10-228","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"GSK Investigational Site","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"GSK Investigational Site","city":"Szczecin Zdunowo 20","zip":"70-891","country":"Poland"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Based on the interim analysis results, the independent data monitoring committee (IDMC) recommended termination of the combination group due to increased toxicity as well as a low likelihood of demonstrating an overall survival benefit at the final analysis.","recruitmentDetails":"This was a multicenter study conducted at 62 centers: 11 in Canada, 5 in Poland, and 46 in the United States from 14 August 2003 to 30 August 2007. A total of 399 participants with advanced non-small cell lung cancer (NSCLC) were enrolled in the study and randomized to treatment.","groups":[{"id":"FG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received intravenous (IV) topotecan 3.5 milligrams per square meter per day (mg/m\\^2/day) and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"FG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (± 2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"202"},{"groupId":"FG001","numSubjects":"197"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"160"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"37"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Serious adverse events (SAE)","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"No clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Decline in Status","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"BG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"399"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"18-40","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}]},{"title":"41-64","categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"245"}]}]},{"title":">=65","categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"149"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"141"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"258"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"23"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"183"},{"groupId":"BG002","value":"367"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Median Time of Overall Survival","description":"Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.","populationDescription":"Intent-to-treat (ITT) population was defined as all participants randomized to one of the two treatment regimens.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"Up to one year from Day -1 (randomization)","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","lowerLimit":"26.1","upperLimit":"35.9"},{"groupId":"OG001","value":"28.6","lowerLimit":"23.6","upperLimit":"36.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9460","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.007","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.813","ciUpperLimit":"1.248","estimateComment":"Unadjusted hazard ratio."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.977","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.788","ciUpperLimit":"1.210","estimateComment":"Adjusted hazard ratio."}]},{"type":"SECONDARY","title":"Number of Participants With One-year Survival","description":"Number of participants with one-year survival were planned to be reported.","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to one year from Day -1 (randomization)","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Median Time to Progression","description":"Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to one year from Day -1 (randomization)","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Response Rate","description":"Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to one year from Day -1 (randomization)","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Response Duration","description":"Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to one year from Day -1 (randomization)","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Time to Response-assessed Every 8 Weeks","description":"Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Every 8 Weeks post randomization","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Assessment of Quality of Life-assessed Every 4 Weeks","description":"The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).","populationDescription":"ITT population. Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Every 4 Weeks post randomization","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.","populationDescription":"mITT Population was defined as all participants who were randomized and received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 16 months","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"195"}]}],"classes":[{"title":"Any AEs","categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"172"}]}]},{"title":"Any SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"49"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities","description":"Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.","populationDescription":"mITT population. Only those participants available at the indicated time points were analyzed.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 16 months","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"195"}]}],"classes":[{"title":"Hemoglobin, Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"107"}]}]},{"title":"Hemoglobin, Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"46"}]}]},{"title":"Hemoglobin, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}]},{"title":"Neutrophils, Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"14"}]}]},{"title":"Neutrophils, Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"7"}]}]},{"title":"Neutrophils, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"7"}]}]},{"title":"Neutrophils, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"}]}]},{"title":"Platelets, Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"10"}]}]},{"title":"Platelets, Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"3"}]}]},{"title":"Platelets, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}]},{"title":"Platelets, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"White blood cell, Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"28"}]}]},{"title":"White blood cell, Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"14"}]}]},{"title":"White blood cell, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"13"}]}]},{"title":"White blood cell, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities","description":"Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.","populationDescription":"mITT population. Only those participants available at the indicated time points were analyzed.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 16 months","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"195"}]}],"classes":[{"title":"Albumin, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"BUN/Urea, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"191"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Creatinine, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Alkaline Phosphatase, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"AST, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"AST, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"ALT, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"ALT, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Bilirubin, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"183"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Sodium, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"}]}]},{"title":"Sodium, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Calcium, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Calcium, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Potassium, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}]},{"title":"Potassium, Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Magnesium, Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"171"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Abnormal Vital Signs Data","description":"Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.","populationDescription":"mITT population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 16 months","groups":[{"id":"OG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."},{"id":"OG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"195"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 16 months","description":"mITT population was analyzed for safety data.","eventGroups":[{"id":"EG000","title":"IV Topotecan + IV Docetaxel","description":"Eligible participants received IV topotecan 3.5 mg/m\\^2/day and IV docetaxel 30 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study.","deathsNumAffected":170,"deathsNumAtRisk":200,"seriousNumAffected":58,"seriousNumAtRisk":200,"otherNumAffected":181,"otherNumAtRisk":200},{"id":"EG001","title":"IV Docetaxel","description":"Eligible participants received single-agent IV docetaxel administered either 75 mg/m\\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study.","deathsNumAffected":165,"deathsNumAtRisk":195,"seriousNumAffected":49,"seriousNumAtRisk":195,"otherNumAffected":166,"otherNumAtRisk":195}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":195}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":200},{"groupId":"EG001","numAffected":7,"numAtRisk":195}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Catheter related complication","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Electrocardiogram ST-T change","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Infusion site phlebitis","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Subclavian vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":0,"numAtRisk":195}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":195}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Clostridial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Perforated ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":200},{"groupId":"EG001","numAffected":1,"numAtRisk":195}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":200},{"groupId":"EG001","numAffected":74,"numAtRisk":195}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":200},{"groupId":"EG001","numAffected":31,"numAtRisk":195}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":200},{"groupId":"EG001","numAffected":28,"numAtRisk":195}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":200},{"groupId":"EG001","numAffected":21,"numAtRisk":195}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":200},{"groupId":"EG001","numAffected":19,"numAtRisk":195}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":200},{"groupId":"EG001","numAffected":10,"numAtRisk":195}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":200},{"groupId":"EG001","numAffected":6,"numAtRisk":195}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":200},{"groupId":"EG001","numAffected":43,"numAtRisk":195}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":200},{"groupId":"EG001","numAffected":40,"numAtRisk":195}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":200},{"groupId":"EG001","numAffected":38,"numAtRisk":195}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":200},{"groupId":"EG001","numAffected":22,"numAtRisk":195}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":200},{"groupId":"EG001","numAffected":11,"numAtRisk":195}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":200},{"groupId":"EG001","numAffected":8,"numAtRisk":195}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":200},{"groupId":"EG001","numAffected":36,"numAtRisk":195}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":200},{"groupId":"EG001","numAffected":29,"numAtRisk":195}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":200},{"groupId":"EG001","numAffected":8,"numAtRisk":195}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":200},{"groupId":"EG001","numAffected":9,"numAtRisk":195}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":200},{"groupId":"EG001","numAffected":4,"numAtRisk":195}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":200},{"groupId":"EG001","numAffected":20,"numAtRisk":195}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":200},{"groupId":"EG001","numAffected":20,"numAtRisk":195}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":200},{"groupId":"EG001","numAffected":10,"numAtRisk":195}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":200},{"groupId":"EG001","numAffected":7,"numAtRisk":195}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":200},{"groupId":"EG001","numAffected":10,"numAtRisk":195}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":200},{"groupId":"EG001","numAffected":21,"numAtRisk":195}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":200},{"groupId":"EG001","numAffected":9,"numAtRisk":195}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":200},{"groupId":"EG001","numAffected":2,"numAtRisk":195}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":200},{"groupId":"EG001","numAffected":37,"numAtRisk":195}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":200},{"groupId":"EG001","numAffected":8,"numAtRisk":195}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":200},{"groupId":"EG001","numAffected":11,"numAtRisk":195}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":200},{"groupId":"EG001","numAffected":35,"numAtRisk":195}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":200},{"groupId":"EG001","numAffected":18,"numAtRisk":195}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":200},{"groupId":"EG001","numAffected":13,"numAtRisk":195}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":200},{"groupId":"EG001","numAffected":20,"numAtRisk":195}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":200},{"groupId":"EG001","numAffected":17,"numAtRisk":195}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":200},{"groupId":"EG001","numAffected":15,"numAtRisk":195}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":200},{"groupId":"EG001","numAffected":14,"numAtRisk":195}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":200},{"groupId":"EG001","numAffected":6,"numAtRisk":195}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":200},{"groupId":"EG001","numAffected":10,"numAtRisk":195}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":200},{"groupId":"EG001","numAffected":28,"numAtRisk":195}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":200},{"groupId":"EG001","numAffected":11,"numAtRisk":195}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":200},{"groupId":"EG001","numAffected":3,"numAtRisk":195}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":200},{"groupId":"EG001","numAffected":13,"numAtRisk":195}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":200},{"groupId":"EG001","numAffected":7,"numAtRisk":195}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The combination group was terminated as per recommendation of IDMC based on the interim analysis results occurred on 04-November-2005. Therefore all the efficacy parameters were not analyzed."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D019772","term":"Topotecan"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D002166","term":"Camptothecin"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}